Trials / Completed
CompletedNCT00234546
Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity
A 24-week Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study of Dysport® Injection for the Treatment of Upper Limb Spasticity in Early Stroke.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 162 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this clinical study is to investigate the efficacy and safety of Dysport® in patients with early onset of upper limb spasticity within 2-12 weeks after stroke.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Botulinum toxin type A | 1 injection, 500 U at day 0. The study will last for 6 months in each patient. |
| DRUG | Placebo | 1 injection at day 0. The study will last for 6 months in each patient. |
Timeline
- Start date
- 2003-02-01
- Completion
- 2007-10-01
- First posted
- 2005-10-07
- Last updated
- 2019-07-26
Locations
5 sites across 5 countries: Hong Kong, Malaysia, Philippines, Singapore, Thailand
Source: ClinicalTrials.gov record NCT00234546. Inclusion in this directory is not an endorsement.